Trinity Precision Technology Co., Ltd. (4534)

Overview

Mochida Pharmaceutical Co., Ltd., established in 1913 and headquartered in Tokyo, Japan, operates in the pharmaceutical and healthcare sectors. The company is dedicated to manufacturing and distributing a wide range of pharmaceutical products aimed at treating various medical conditions, including cardiovascular diseases, obstetrics and gynecology issues, dermatology, psychiatry, and gastroenterology. It not only focuses on the Japanese market but also emphasizes research and development to innovate healthcare solutions, including medical devices for specialized treatments.

Products and Services

Mochida Pharmaceutical Co., Ltd. offers a comprehensive portfolio of pharmaceuticals and healthcare products, including:

• Lialda: A medication for the treatment of ulcerative colitis, offering patients relief from this chronic inflammatory bowel disease.
• Goofice and Movicol: Designed for the treatment of chronic constipation, these products provide solutions to improve bowel movements and comfort.
• Lexapro: An antidepressant drug that helps to manage and treat depression and anxiety, improving the mental health of patients.
• Epadel: A drug aimed at treating hyperlipidemia and arteriosclerosis obliterans, contributing to cardiovascular health maintenance.
• Urece: Targeted at patients suffering from gout and hyperuricemia, this product aids in managing uric acid levels in the body.
• Treprost: For the treatment of pulmonary arterial hypertension, this medication helps in improving symptoms and quality of life for patients with this condition.
• Atelec: A calcium channel blocker with a long-acting hypotensive effect, used to control high blood pressure and prevent associated risks.
• Tramcet: An analgesic that is effective in managing chronic pain and post-tooth extraction pain, providing relief to patients.
• Heparin Sodium MOCHIDA: An anticoagulant agent used in the prevention and treatment of thromboembolic diseases.
• Beselna: A therapeutic agent for treating condyloma acuminatum and actinic keratosis, addressing skin conditions with precision.
• Dinagest: A therapeutic agent for managing endometriosis, adenomyosis, and dysmenorrhea, offering relief from painful menstrual symptoms.

Additionally, the company is at the forefront of developing innovative solutions, including:

• Mesalazine, for the treatment of ulcerative colitis.
• Ethyl icosapentate, aimed at treating hypertriglyceridemia.
• Daridorexant, for addressing insomnia.
• Dotinurad, for managing gout and hyperuricemia.
• Treprostinil, for treating pulmonary hypertension associated with interstitial lung disease.
• Development of medical devices like dMD-001, meant for the treatment of articular cartilage lesions, and dMD-002, targeted at treating cavernous nerve injury.

Besides pharmaceuticals, Mochida also offers a range of skin care, baby care, personal care, and nursing products, catering to diverse healthcare and wellness needs.